Lif/lifr antagonist in oncology and nonmalignant diseases
AssigneeEvestra, Inc.
InventorsHareesh Nair, Bindu Santhamma, Gulzar Ahmed, Klaus Nickisch
Life of this patent
Estimating the term…
Abstract
Described herein are methods of using compounds that inhibit leukemia inhibitory factor (LIF) and/or block of the leukemia inhibitory factor receptor for treatment of liver fibrosis, proliferation of spinal tumors, and in combination therapy with an immunotherapeutic agent.
Claims18
1-19. (canceled)
A method of treating cancer in a subject comprising administering to a subject a medicament comprising an effective amount of an immunotherapeutic agent and a small molecule compound that inhibits leukemia inhibitory factor or leukemia inhibitory factor receptor.
A method of treating cancer in a subject comprising administering to a subject a medicament comprising an effective amount of a PD-1 or PD-L1 inhibitor and a small molecule compound that inhibits leukemia inhibitory factor or leukemia inhibitory factor receptor.
36-42. (canceled)
Dependencies are inferred from the claim text.